{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:36:24Z","timestamp":1791128184834,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T00:00:00Z","timestamp":1334188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0034372","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T21:10:41Z","timestamp":1334265041000},"page":"e34372","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":78,"title":["Hepatitis C Viral Evolution in Genotype 1 Treatment-Na\u00efve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials"],"prefix":"10.1371","volume":"7","author":[{"given":"Tara L.","family":"Kieffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug J.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Tigges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Dierynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Spanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dorrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambang","family":"Adiwijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ghys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Adda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,4,12]]},"reference":[{"key":"ref1","article-title":"INCIVEK [US product insert]. Vertex website.","year":"2011"},{"key":"ref2","article-title":"INCIVO [EU Summary of product characteristics]. European Medicines Agency (EMA) website.","year":"2011"},{"key":"ref3","article-title":"INCIVEK [Canadian product monograph]. Vertex website.","year":"2011"},{"key":"ref4","article-title":"TELAVIC [Japanese press release]. Mitsubishi website.","year":"2011"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nbt.2020","article-title":"Discovery and development of telaprevir: an NS3-4a protease inhibitor for treating genotype 1 chronic hepatitis C virus.","volume":"29","author":"AD Kwong","year":"2011","journal-title":"Nat Biotechnol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.","volume":"50","author":"RB Perni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1128\/AAC.50.5.1813-1822.2006","article-title":"VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells.","volume":"50","author":"K Lin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection.","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.","volume":"132","author":"C Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.","volume":"360","author":"C H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"ref12","first-page":"2157","article-title":"Hepatitis C.","author":"SC Ray","year":"2009"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.","volume":"88","author":"N Ogata","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus.","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2004-828672","article-title":"Molecular virology of hepatitis B virus.","volume":"24","author":"S Locarnini","year":"2004","journal-title":"Semin Liver Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkh292","article-title":"A long-term latent reservoir for HIV-1: discovery and clinical implications.","volume":"54","author":"JD Siliciano","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection.","volume":"5","author":"B Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.","volume":"360","author":"JG McHutchinson","year":"2009","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.","volume":"360","author":"C H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection.","volume":"362","author":"JG McHutchinson","year":"2010","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/hep.24549","article-title":"Retreatment with telaprevir combination therapy in hepatitic C patients with well-characterized prior treatment-response.","volume":"54","author":"A Muir","year":"2011","journal-title":"Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.","volume":"140","author":"P Marcellin","year":"2011","journal-title":"Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection.","volume":"365","author":"KE Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-na\u00efve subjects.","volume":"198","author":"D Bartels","year":"2008","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatits C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.","volume":"279","author":"C Lin","year":"2004","journal-title":"J Bio Chem"},{"issue":"4 Suppl","key":"ref27","first-page":"1138A","article-title":"No compensatory fitness mutations selected in NS3\/4A protease cleavage sites during treatment with telaprevir, Peg-IFN-Alfa-2A, and ribavirin in phase II studies of treatment-na\u00efve HCV genotype 1-infected patients.","volume":"48","author":"EZ Zhang","year":"2008","journal-title":"Hepatology"},{"key":"ref28","first-page":"6","article-title":"Characterization of resistant variants in treatment-naive and experienced genotype 1 HCV patients in phase 2 trials of telaprevir\/Peg-IFN\/RBV.","volume":"5","author":"TL Kieffer","year":"2010","journal-title":"Rev Antiviral Ther Infect Dis"},{"issue":"Suppl 1","key":"ref29","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60010-X","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.","volume":"54","author":"JC Sullivan","year":"2011","journal-title":"Hepatol"},{"issue":"Suppl 1","key":"ref30","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S0168-8278(11)61204-X","article-title":"Characterization of HCV variants in non-SVR patients in the REALIZE Study Suggests that telaprevir exhibits a consistent resistance profile irrespective of a lead-in.","volume":"54","author":"S De Meyer","year":"2011","journal-title":"J Hepatol"},{"issue":"4 Suppl","key":"ref31","first-page":"436A","article-title":"Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study.","volume":"52","author":"S Zeuzem","year":"2010","journal-title":"Hepatology"},{"key":"ref32","article-title":"Long-term follow-up of HCV variants in patients treated with 14 days of telaprevir monotherapy.","author":"J de Bruijne","year":"2010"},{"issue":"Suppl. 1","key":"ref33","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1016\/S0168-8278(11)61244-0","article-title":"Long-term follow-up of chronic hepatitis C infected patients treated with telaprevir: evaluation of persistence of resistant variants by ultra-deep sequencing.","volume":"54","author":"XV Thomas","year":"2011","journal-title":"J Hepatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0034372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T13:16:17Z","timestamp":1589030177000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0034372"}},"subtitle":[],"editor":[{"given":"John E.","family":"Tavis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,4,12]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0034372","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,12]]}}}